Truist raises Integra Lifesciences target to $19
Truist Securities analyst Ravi Misra maintains a Hold rating on Integra Lifesciences (NASDAQ: IART) and raises the price target to $19 from $14, signaling a revised valuation outlook.
*this image is generated using AI for illustrative purposes only.
Truist Securities analyst Ravi Misra has maintained a Hold rating on Integra Lifesciences (NASDAQ: IART) while raising the price target for the stock. The new target stands at $19, an increase from the previous estimate of $14. This adjustment reflects a revised valuation outlook for the company's shares.
The decision to retain the Hold rating suggests that while the price potential has increased, the stock may still present a balanced risk-reward profile at current levels. The raised price target indicates a more optimistic view of the company's future performance compared to the prior assessment.
Price Target Details
The following table outlines the revised price target set by Truist Securities:
| Metric | Value |
|---|---|
| Rating | Hold |
| New Price Target | $19 |
| Previous Price Target | $14 |
Integra Lifesciences operates in the medical technology sector. The updated target provides investors with a new benchmark for the stock's potential trajectory over the near term.
What specific factors drove the 35% increase in the price target despite maintaining a Hold rating?
How might Integra Lifesciences' upcoming product pipeline influence future rating upgrades?
What are the key risks that could prevent the stock from reaching the new $19 price target?
15
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
